# NCT03898180 (NCT03898180)

> Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03898180
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Urothelial Carcinoma
- Interventions: Pembrolizumab; Lenvatinib; Placebo for lenvatinib
- Enrollment: 505
- Primary outcome: Progression-free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 11
- YouTube: 2
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03898180

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03898180", "email": "<work email>"}; the inbox owner confirms by the emailed link.